Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

I-MOVE-COVID-19 primary care study team

doi:10.2807/1560-7917.ES.2021.26.29.2100670

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

I-MOVE-COVID-19 primary care study team

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

40 Citations (Scopus)

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

Original language	English
Journal	Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Volume	26
Issue number	29
DOIs	https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670
Publication status	Published - 22 Jul 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adult
Aged
COVID-19
COVID-19 Vaccines
Europe
Humans
Primary Health Care
SARS-CoV-2

Access to Document

10.2807/1560-7917.ES.2021.26.29.2100670Licence: CC BY

Handle.net

Persistent link

Cite this

I-MOVE-COVID-19 primary care study team (2021). Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 26(29). https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670

@article{d1687d39fcac408aa10310f1f2a4250f,

title = "Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021",

abstract = "We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62\% (95\% CI: 45-74) for one dose only and 89\% (95\% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.",

keywords = "Adult, Aged, COVID-19, COVID-19 Vaccines, Europe, Humans, Primary Health Care, SARS-CoV-2",

author = "\{I-MOVE-COVID-19 primary care study team\} and Esther Kissling and Mariette Hooiveld and \{Sandonis Mart{\'i}n\}, Virginia and Iv{\'a}n Mart{\'i}nez-Baz and Naoma William and Ana-Maria Vilcu and Clara Mazagatos and Lisa Domegan and \{de Lusignan\}, Simon and Adam Meijer and Ausenda Machado and Mia Brytting and Itziar Casado and Murray, \{Josephine-L K\} and Sylvie Belhillil and Amparo Larrauri and Joan O'Donnell and Ruby Tsang and \{de Lange\}, Marit and Rodrigues, \{Ana Paula\} and Maximilian Riess and Jes{\'u}s Castilla and Mark Hamilton and Alessandra Falchi and Francisco Pozo and Linda Dunford and Jade Cogdale and Tessa Jansen and Raquel Guiomar and Theresa Enkirch",

year = "2021",

month = jul,

day = "22",

doi = "10.2807/1560-7917.ES.2021.26.29.2100670",

language = "English",

volume = "26",

journal = "Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin",

issn = "1025-496X",

publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",

number = "29",

}

I-MOVE-COVID-19 primary care study team 2021, 'Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021', Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, vol. 26, no. 29. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. / I-MOVE-COVID-19 primary care study team.
In: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, Vol. 26, No. 29, 22.07.2021.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care

T2 - I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

AU - I-MOVE-COVID-19 primary care study team

AU - Kissling, Esther

AU - Hooiveld, Mariette

AU - Sandonis Martín, Virginia

AU - Martínez-Baz, Iván

AU - William, Naoma

AU - Vilcu, Ana-Maria

AU - Mazagatos, Clara

AU - Domegan, Lisa

AU - de Lusignan, Simon

AU - Meijer, Adam

AU - Machado, Ausenda

AU - Brytting, Mia

AU - Casado, Itziar

AU - Murray, Josephine-L K

AU - Belhillil, Sylvie

AU - Larrauri, Amparo

AU - O'Donnell, Joan

AU - Tsang, Ruby

AU - de Lange, Marit

AU - Rodrigues, Ana Paula

AU - Riess, Maximilian

AU - Castilla, Jesús

AU - Hamilton, Mark

AU - Falchi, Alessandra

AU - Pozo, Francisco

AU - Dunford, Linda

AU - Cogdale, Jade

AU - Jansen, Tessa

AU - Guiomar, Raquel

AU - Enkirch, Theresa

PY - 2021/7/22

Y1 - 2021/7/22

N2 - We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

AB - We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

KW - Adult

KW - Aged

KW - COVID-19

KW - COVID-19 Vaccines

KW - Europe

KW - Humans

KW - Primary Health Care

KW - SARS-CoV-2

U2 - 10.2807/1560-7917.ES.2021.26.29.2100670

DO - 10.2807/1560-7917.ES.2021.26.29.2100670

M3 - Article (Academic Journal)

C2 - 34296676

SN - 1025-496X

VL - 26

JO - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

IS - 29

ER -

I-MOVE-COVID-19 primary care study team. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021 Jul 22;26(29). doi: 10.2807/1560-7917.ES.2021.26.29.2100670

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Abstract

UN SDGs

Keywords

Access to Document

Handle.net

Fingerprint

Cite this